FDA — authorised 28 February 2022
- Application: NDA215457
- Marketing authorisation holder: KALEO INC
- Status: supplemented
FDA authorised Naloxone Hydrochloride Injection, USP on 28 February 2022
Yes. FDA authorised it on 28 February 2022.
KALEO INC holds the US marketing authorisation.